GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Gross Margin %

Avacta Group (LSE:AVCT) Gross Margin % : 39.58% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Avacta Group's Gross Profit for the six months ended in Dec. 2023 was £4.50 Mil. Avacta Group's Revenue for the six months ended in Dec. 2023 was £11.36 Mil. Therefore, Avacta Group's Gross Margin % for the quarter that ended in Dec. 2023 was 39.58%.

Warning Sign:

Avacta Group PLC gross margin has been in long-term decline. The average rate of decline per year is -2.8%.


The historical rank and industry rank for Avacta Group's Gross Margin % or its related term are showing as below:

LSE:AVCT' s Gross Margin % Range Over the Past 10 Years
Min: 48.37   Med: 66.51   Max: 75.03
Current: 48.37


During the past 13 years, the highest Gross Margin % of Avacta Group was 75.03%. The lowest was 48.37%. And the median was 66.51%.

LSE:AVCT's Gross Margin % is ranked worse than
62.73% of 746 companies
in the Biotechnology industry
Industry Median: 59.74 vs LSE:AVCT: 48.37

Avacta Group had a gross margin of 39.58% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Avacta Group was -2.80% per year.


Avacta Group Gross Margin % Historical Data

The historical data trend for Avacta Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Gross Margin % Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.68 55.13 68.58 75.03 48.37

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.54 95.58 47.63 56.76 39.58

Competitive Comparison of Avacta Group's Gross Margin %

For the Biotechnology subindustry, Avacta Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avacta Group's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avacta Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Avacta Group's Gross Margin % falls into.



Avacta Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Avacta Group's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=11.2 / 23.247
=(Revenue - Cost of Goods Sold) / Revenue
=(23.247 - 12.003) / 23.247
=48.37 %

Avacta Group's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=4.5 / 11.358
=(Revenue - Cost of Goods Sold) / Revenue
=(11.358 - 6.862) / 11.358
=39.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Avacta Group  (LSE:AVCT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Avacta Group had a gross margin of 39.58% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Avacta Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Avacta Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (LSE:AVCT) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines